Seeking Alpha

Results from study of Portola's factor Xa inhibitor antidote presented at ASH

  • Portola Pharmaceuticals (PTLA +0.1%) says additional results from a Phase 2 study show andexanet alfa immediately reverses the anticoagulation activity of Xarelto.
  • No SAEs were observed.
  • Here's PTLA commenting: "Andexanet alfa has the potential to be a first-in-class universal antidote designed to reverse the anticoagulant activity of Factor Xa inhibitors in patients who experience an uncontrolled bleeding episode or who require emergency surgery."
  • The company estimates as many as 500K patients in the U.S., Japan, and the EU could benefit from such an antidote by 2020. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs